Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18096565rdf:typepubmed:Citationlld:pubmed
pubmed-article:18096565lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C1708063lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0442711lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0332283lld:lifeskim
pubmed-article:18096565lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:18096565pubmed:issue4lld:pubmed
pubmed-article:18096565pubmed:dateCreated2008-3-26lld:pubmed
pubmed-article:18096565pubmed:abstractTextGefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression.lld:pubmed
pubmed-article:18096565pubmed:languageenglld:pubmed
pubmed-article:18096565pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:citationSubsetIMlld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096565pubmed:statusMEDLINElld:pubmed
pubmed-article:18096565pubmed:monthAprlld:pubmed
pubmed-article:18096565pubmed:issn1569-8041lld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:MayerMMlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:MackKKlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:WidmerLLlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:RibiKKlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:RauchDDlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:StahelRRlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:PlessMMlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:StuppRRlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:TapieGGlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:BetticherD...lld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:JostLLlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:BubendorfLLlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:LerchSSlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:D'AddarioGGlld:pubmed
pubmed-article:18096565pubmed:authorpubmed-author:BihlMMlld:pubmed
pubmed-article:18096565pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18096565pubmed:volume19lld:pubmed
pubmed-article:18096565pubmed:ownerNLMlld:pubmed
pubmed-article:18096565pubmed:authorsCompleteYlld:pubmed
pubmed-article:18096565pubmed:pagination739-45lld:pubmed
pubmed-article:18096565pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:meshHeadingpubmed-meshheading:18096565...lld:pubmed
pubmed-article:18096565pubmed:year2008lld:pubmed
pubmed-article:18096565pubmed:articleTitleMulticenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.lld:pubmed
pubmed-article:18096565pubmed:affiliationDepartment of Oncology, Kantonsspital St.Gallen, St. Gallen, Switzerland. g.daddario@hin.chlld:pubmed
pubmed-article:18096565pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18096565pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18096565pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:18096565pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18096565lld:pubmed